The Liposomal Difference To solve the absorption problem, we use liposomal delivery
Patients with ulcerative colitis may benefit from slower titration schedules compared to standard dosing guidelines
After one to two weeks of every-other-day use, you can comfortably move to daily application
Several GLP-1 receptor agonists are currently licensed for use in the UK, including semaglutide (Ozempic, Wegovy, Rybelsus), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), exenatide (Bydureon BCise), and lixisenatide (Lyxumia)
11 These findings underscore the potential of dual incretin agonism to achieve greater and more sustained weight reduction in individuals with obesity
Tirzepatide may produce greater average weight loss because it targets both GLP-1 and GIP receptors instead of only GLP-1